Publication: Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection
2
Issued Date
2015-12-01
Resource Type
ISSN
18729096
01663542
01663542
Other identifier(s)
2-s2.0-84946907363
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antiviral Research. Vol.124, (2015), 61-68
Suggested Citation
Ririn Ramadhany, Itaru Hirai, Tadahiro Sasaki, Ken Ichiro Ono, Pongrama Ramasoota, Kazuyoshi Ikuta, Takeshi Kurosu Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection. Antiviral Research. Vol.124, (2015), 61-68. doi:10.1016/j.antiviral.2015.10.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36043
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection
Abstract
© 2015 Published by Elsevier B.V. Antibody-dependent enhancement (ADE) of dengue virus (DENV) infectivity is thought to play a crucial role in severe dengue disease. It occurs when pre-existing sub-neutralizing anti-DENV antibody (Ab) produced from a primary infection encounters a DENV serotype different from that of the initial infection and forms immune complexes, which enable the efficient infection of Fcγ receptor-bearing cells. However, the exact role played by Abs during a secondary infection of patients remains unknown. We previously obtained a broadly cross-reactive neutralizing IgG1 human monoclonal anti-DENV envelope (E) Ab (HuMAb) D23-1G7C2-IgG1 from a DENV-infected patient; however, D23-1G7C2-IgG1 had ADE activity. With the aim of being able to reduce the ADE activity, we exchanged the Fc region of D23-1G7C2 to generate Abs bearing each of the three other IgG subclasses (IgG2-4). In addition, N297A, a mutation known to reduce the affinity of the IgG1 Fc region for Fcγ receptors, was introduced into D23-1G7C2-IgG1. Swapping D23-1G7C2-IgG1 to IgG2 or IgG4 subclasses reduced ADE activity in FcγRI and FcγRII-bearing THP-1 cells. By contrast, in FcγRII-bearing K562 cells, the change to IgG2 increased ADE activity. Introducing the N297A mutation into D23-1G7C2-IgG1 resulted in a marked reduction in ADE activity in both cell types. Compared to D23-1G7C2-IgG1, D23-1G7C2-IgG1-N297A was less protective in IFN-α/β/γ receptor knockout mice infected with a lethal dose of recombinant chimeric DENV, carrying prME of DENV-2 in Japanese encephalitis virus (80% vs. 40% survival, respectively). These observations provide valuable information regarding the use of recombinant Abs as therapeutics.